195 related articles for article (PubMed ID: 36791204)
1. Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation.
Aw WY; Cho C; Wang H; Cooper AH; Doherty EL; Rocco D; Huang SA; Kubik S; Whitworth CP; Armstrong R; Hickey AJ; Griffith B; Kutys ML; Blatt J; Polacheck WJ
Sci Adv; 2023 Feb; 9(7):eade8939. PubMed ID: 36791204
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
Ren AA; Snellings DA; Su YS; Hong CC; Castro M; Tang AT; Detter MR; Hobson N; Girard R; Romanos S; Lightle R; Moore T; Shenkar R; Benavides C; Beaman MM; Müller-Fielitz H; Chen M; Mericko P; Yang J; Sung DC; Lawton MT; Ruppert JM; Schwaninger M; Körbelin J; Potente M; Awad IA; Marchuk DA; Kahn ML
Nature; 2021 Jun; 594(7862):271-276. PubMed ID: 33910229
[TBL] [Abstract][Full Text] [Related]
3. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
4. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
Silva JM; Deuker MM; Baguley BC; McMahon M
Pigment Cell Melanoma Res; 2017 May; 30(3):353-367. PubMed ID: 28233937
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
7. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
8. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
9. mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.
Li J; Liu J; Song J; Wang X; Weiss HL; Townsend CM; Gao T; Evers BM
Am J Physiol Cell Physiol; 2011 Jul; 301(1):C213-26. PubMed ID: 21508335
[TBL] [Abstract][Full Text] [Related]
10. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
11. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.
Saci A; Cantley LC; Carpenter CL
Mol Cell; 2011 Apr; 42(1):50-61. PubMed ID: 21474067
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S
J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815
[TBL] [Abstract][Full Text] [Related]
13. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for capillary-venous malformations.
Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
[TBL] [Abstract][Full Text] [Related]
15. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
16. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
Khor ES; Wong PF
Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive phenotypic and genomic characterization of venous malformations.
Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
[TBL] [Abstract][Full Text] [Related]
19. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations.
Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP
Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
Gulhati P; Bowen KA; Liu J; Stevens PD; Rychahou PG; Chen M; Lee EY; Weiss HL; O'Connor KL; Gao T; Evers BM
Cancer Res; 2011 May; 71(9):3246-56. PubMed ID: 21430067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
